As cannabis regulations evolve, operators are reassessing tax strategy, financial systems, operational controls, and long-term planning. Our complimentary Rescheduling Readiness Consultation is designed to help you evaluate where your business stands today and what may deserve attention moving forward.
We’ve been preparing for this potential shift, and our team is ready to help you think through what comes next as part of your planning.
Evaluate how evolving federal treatment of medical cannabis may impact tax strategy and financial planning as guidance develops.
Review potential amended filing or restructuring opportunities based on your operating structure and future IRS guidance.
Model potential cash flow impacts and evaluate opportunities to improve liquidity, reinvestment, or debt positioning.
Strengthen payroll, reporting, documentation, and financial systems that support operational discipline, compliance readiness, and long-term scalability.
Improve visibility into cash flow, credit, collections, and internal controls.
Implement banking and payment strategies that support stability today and flexibility moving forward.
Evaluate financing, refinancing, and capital structure opportunities that may emerge as the regulatory and lending environment evolves.
Engage with lending partners who understand cannabis-specific operating realities.
Support longer-term planning in an evolving regulatory environment.
Evaluate whether your current entity structure and operational model are positioned for a changing medical and adult-use regulatory environment.
Engage with lending partners who understand cannabis-specific operating realities.
Identify areas where SOPs, documentation, or reporting practices may require strengthening as expectations evolve.
The U.S. Department of Justice announced an order moving certain state-licensed medical marijuana activity and FDA-approved marijuana-derived drug products to Schedule III under federal law. This is a meaningful development for qualifying medical activity, but it does not federally legalize cannabis and does not currently extend to adult-use cannabis.
Potentially. Because Section 280E applies to Schedule I and II substances, qualifying medical activity moved to Schedule III may receive different tax treatment. Implementation details, business structure, and IRS guidance will matter. Operators should consult qualified tax advisors based on their specific facts and circumstances.
No. Banking cannabis businesses still requires strong compliance practices, including BSA/AML controls, due diligence, transaction monitoring, and ongoing documentation. This update may improve industry sentiment over time, but it does not eliminate core banking requirements today.
Over time, yes. If certain operators benefit from improved cash flow, stronger financial statements, or lower tax burden, lenders and investors may evaluate opportunities differently. Businesses with organized financials, disciplined operations, and clear reporting are typically best positioned first.
Operators should focus on strong fundamentals: accurate financial reporting, reliable bookkeeping, better cash visibility, clear entity and revenue segmentation, realistic tax planning, and readiness to move quickly if broader reform follows.
No. Federal and state compliance, reporting, and oversight requirements remain in place. This update does not reduce obligations related to licensing, financial reporting, or transaction monitoring. In some cases, increased federal recognition may lead to greater expectations around accuracy, controls, and documentation.
Yes. Additional federal proceedings have been announced regarding broader marijuana rescheduling. While outcomes and timing remain uncertain, many operators are using this moment to improve readiness in case broader reform follows.
